PHAR
USDPharming Group N.V. ADS each representing 10 ordinary shares
실시간 가격
가격 차트
핵심 지표
시장 지표
시가
$11.050
고가
$11.140
저가
$11.050
거래량
0.00M
기업 기본 정보
시가총액
767.1M
산업
생명공학
국가
Netherlands
거래 통계
평균 거래량
0.00M
거래소
NGM
통화
USD
52주 범위
관련 뉴스
Pharming Group reports first quarter 2025 financial results and provides business update
First quarter 2025 total revenues increased by 42% to US$79.1 million, compared to the first quarter 2024 RUCONEST® revenue increased by 49% to US$68.6 million, compared to the first quarter 2024, reflecting
Pharming Group announces upcoming presentations at the 2025 Annual Meeting of the Clinical Immunology Society (CIS)
Leiden, the Netherlands, April 25, 2025: Pharming Group N.V. ("Pharming" or "the Company") (NASDAQ:PHAR) announces the following presentations by the Company or its collaborators at the 2025 Annual Meeting of the
Pharming receives positive recommendation from NICE for Joenja®▼(leniolisib) as a treatment for APDS
For media and investors only Joenja® is the first and only medicine specifically for APDS to be reimbursed within the NHS Recommended for adult and pediatric patients 12 years of age and older with activated
